Skip to main content

Table 1 Patient characteristics

From: Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital

Age

Mean (sd)

56.5 (11.1)

Distance from PMH (km)

Median (range) [IQR]

22.2 (0.6–1480.2) [12.7–42.7]

Gender

Male:Female

339:328 (50.8:49.2)

Tumor site

Breast

46 (6.9)

 

GI colorectal

172 (25.8)

 

GI non-colorectal

178 (26.7)

 

Genitourinary

36 (5.4)

 

Gynaecologic

74 (11.1)

 

Head and neck

23 (3.5)

 

Lung

57 (8.6)

 

Sarcoma

8 (1.2)

 

Skin and melanoma

11 (1.7)

 

Unknown primary

42 (6.3)

 

Multiple sites*

6 (0.9)

 

Other**

14 (2.1)

Number of prior regimens

0

68 (10.2)

 

1

210 (31.5)

 

2

186 (27.9)

 

3

116 (17.4)

 

4

52 (7.8)

 

5

24 (3.6)

 

6+

11 (1.7)

PS

0

211 (31.6)

 

1

318 (47.7)

 

2

87 (13.0)

 

3

49 (7.4)

 

4

2 (0.3)

Entered on trial

Yes:No

197:470 (29.5:70.5)

Referring physician

PMH Oncologist

328 (49.2)

 

External Oncologist

310 (46.5)

 

Family Physician

12 (1.8)

 

Other Physician

13 (2.0)

 

Unknown

4 (0.6)

  1. * Multiple sites were GI non-colorectal/gastric/lymphoma, GI non-colorectal/prostate, lung/breast, lung/esophageal, skin and melanoma/leukemia, unknown/prostate
  2. ** Others were adrenal [1], GI stromal [1], lymphoma [2], merkel cell [1] mesothelioma [3], mixed germ cell [1], neuroendocrine [2], pseudomyxoma [1], thyroid [1] and thymus [1]